Latest Biotechnology News

Page 21 of 33
Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.
Ada Torres
Ada Torres
2 July 2025
Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.
Ada Torres
Ada Torres
2 July 2025
Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.
Ada Torres
Ada Torres
1 July 2025
Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.
Ada Torres
Ada Torres
1 July 2025
Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.
Ada Torres
Ada Torres
30 June 2025
Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.
Ada Torres
Ada Torres
30 June 2025
PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.
Ada Torres
Ada Torres
27 June 2025
Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.
Ada Torres
Ada Torres
26 June 2025
Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.
Ada Torres
Ada Torres
24 June 2025
INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.
Ada Torres
Ada Torres
23 June 2025
PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.
Ada Torres
Ada Torres
23 June 2025
Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.
Ada Torres
Ada Torres
23 June 2025